Halozyme Therapeutics, Inc. $HALO Stake Boosted by Intech Investment Management LLC

Intech Investment Management LLC increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 32.7% during the fourth quarter, HoldingsChannel reports. The firm owned 197,226 shares of the biopharmaceutical company’s stock after acquiring an additional 48,559 shares during the period. Intech Investment Management LLC’s holdings in Halozyme Therapeutics were worth $13,273,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of HALO. Larson Financial Group LLC boosted its position in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the period. Clearstead Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the last quarter. Harbour Investments Inc. lifted its holdings in shares of Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $52,000. Finally, Wexford Capital LP acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $70,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $66.54 on Friday. The stock’s fifty day moving average is $66.14 and its 200-day moving average is $68.76. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock has a market capitalization of $7.89 billion, a PE ratio of 23.94, a PEG ratio of 0.28 and a beta of 0.89. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter in the prior year, the firm posted $1.11 earnings per share. The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HALO. Morgan Stanley reduced their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. HC Wainwright boosted their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Benchmark upped their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Finally, Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $49,322,187.20. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $63.48, for a total value of $103,155.00. Following the completion of the sale, the director owned 38,498 shares of the company’s stock, valued at $2,443,853.04. This trade represents a 4.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.